ASTERDM.NS
Aster DM Healthcare Limited [ASTERDM.NS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ASTERDM.NS Stock Summary
Top 10 Correlated Stocks
ASTERDM.NS
In the News
ASTERDM.NS Financial details
Company Rating
Buy
Market Cap
243.86B
Income
3.24B
Revenue
135.05B
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
30.33K
Optionable
No
Shortable
Yes
Earnings
08 Apr 2024
P/E
71.29
Forward P/E
-
PEG
-18.53
P/S
1.57
P/B
4.63
P/C
-
P/FCF
30425.56
Quick Ratio
0.56
Current Ratio
0.97
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
6.51
EPS next Y
-
EPS next Q
-
EPS this Y
-19.28%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
5.19%
Revenue last 5Y
8.43%
Revenue Q/Q
11.88%
EPS Q/Q
-680.65%
-
-
-
-
SMA20
12.93%
SMA50
13.72%
SMA100
44.25%
Inst Own
-
Inst Trans
-
ROA
2%
ROE
13%
ROC
0.09%
Gross Margin
71%
Oper. Margin
7%
Profit Margin
2%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
240.4-500.0
52W High
+4.36%
52W Low
+117.42%
RSI
73
Rel Volume
5.61
Avg Volume
1.06M
Volume
5.95M
Perf Week
14.24%
Perf Month
12.93%
Perf Quarter
46.2%
Perf Half Y
55.37%
-
-
-
-
Beta
0.606
-
-
Volatility
20.8%, 33.03%
Prev Close
0.36%
Price
521.8
Change
-2.13%
ASTERDM.NS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
| Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 158.59 | 174.04 | 173.24 | 206.26 | 239.95 | |
| Net income per share | 6.63 | 5.51 | 2.97 | 10.58 | 8.54 | |
| Operating cash flow per share | 11.62 | 24.36 | 31.58 | 26.42 | 36.88 | |
| Free cash flow per share | 0.11 | 13.79 | 23.05 | 15.4 | 19.82 | |
| Cash per share | 4.97 | 3.45 | 6.16 | 8.48 | 12.64 | |
| Book value per share | 64.01 | 65.17 | 67.87 | 79.53 | 89.44 | |
| Tangible book value per share | 54.04 | 48.46 | 50.95 | 62.7 | 67.02 | |
| Share holders equity per share | 64.01 | 65.17 | 67.87 | 79.53 | 89.44 | |
| Interest debt per share | 58.7 | 117.88 | 102.55 | 103.85 | 121.25 | |
| Market cap | 77.35B | 47.77B | 68.3B | 98.18B | 119.7B | |
| Enterprise value | 102.96B | 102.31B | 113.75B | 143.81B | 172.92B | |
| P/E ratio | 23.22 | 17.27 | 46.23 | 18.67 | 28.17 | |
| Price to sales ratio | 0.97 | 0.55 | 0.79 | 0.96 | 1 | |
| POCF ratio | 13.25 | 3.91 | 4.35 | 7.47 | 6.53 | |
| PFCF ratio | 1.36K | 6.9 | 5.96 | 12.83 | 12.14 | |
| P/B Ratio | 2.41 | 1.46 | 2.03 | 2.48 | 2.69 | |
| PTB ratio | 2.41 | 1.46 | 2.03 | 2.48 | 2.69 | |
| EV to sales | 1.29 | 1.17 | 1.32 | 1.4 | 1.45 | |
| Enterprise value over EBITDA | 11.76 | 8.19 | 10.08 | 9.39 | 10.51 | |
| EV to operating cash flow | 17.64 | 8.36 | 7.25 | 10.95 | 9.43 | |
| EV to free cash flow | 1.81K | 14.78 | 9.93 | 18.79 | 17.54 | |
| Earnings yield | 0.04 | 0.06 | 0.02 | 0.05 | 0.04 | |
| Free cash flow yield | 0 | 0.14 | 0.17 | 0.08 | 0.08 | |
| Debt to equity | 0.87 | 1.71 | 1.42 | 1.24 | 1.28 | |
| Debt to assets | 0.31 | 0.45 | 0.41 | 0.39 | 0.38 | |
| Net debt to EBITDA | 2.92 | 4.37 | 4.03 | 2.98 | 3.24 | |
| Current ratio | 1.36 | 1.1 | 1.14 | 1.15 | 1.06 | |
| Interest coverage | 3.67 | 2.16 | 1.53 | 3.31 | 2.39 | |
| Income quality | 1.42 | 3.5 | 7.65 | 2.06 | 3.43 | |
| Dividend Yield | 0 | 0.02 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0.26 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.01 | 0.01 | 0.09 | 0.09 | 0.09 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.11 | 0.1 | 0.11 | 0.11 | 0.1 | |
| Capex to operating cash flow | -0.99 | -0.43 | -0.27 | -0.42 | -0.46 | |
| Capex to revenue | -0.07 | -0.06 | -0.05 | -0.05 | -0.07 | |
| Capex to depreciation | -1.89 | -0.91 | -0.69 | -0.86 | -1.09 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 97.75 | 89.88 | 67.38 | 137.6 | 131.13 | |
| ROIC | 0.09 | 0.06 | 0.04 | 0.07 | 0.05 | |
| Return on tangible assets | 0.04 | 0.02 | 0.01 | 0.05 | 0.03 | |
| Graham Net | -53.55 | -124.13 | -110.42 | -110.93 | -140.5 | |
| Working capital | 9.49B | 3.74B | 4.33B | 5.38B | 2.66B | |
| Tangible asset value | 27.13B | 24.33B | 25.32B | 31.17B | 33.33B | |
| Net current asset value | -16.4B | -46.24B | -41.8B | -39.67B | -50.99B | |
| Invested capital | 0.87 | 1.71 | 1.42 | 1.24 | 1.28 | |
| Average receivables | 22.57B | 25.24B | 22.84B | 21.38B | 22.45B | |
| Average payables | 9.3B | 11.54B | 16.61B | 20.73B | 25.53B | |
| Average inventory | 6.8B | 8.47B | 9.05B | 9.37B | 11.66B | |
| Days sales outstanding | 119.31 | 102.1 | 90.01 | 76.66 | 71.46 | |
| Days payables outstanding | 120.77 | 139.5 | 288.98 | 265.77 | 308.77 | |
| Days of inventory on hand | 87.19 | 103.6 | 121.02 | 128.7 | 134.93 | |
| Receivables turnover | 3.06 | 3.58 | 4.06 | 4.76 | 5.11 | |
| Payables turnover | 3.02 | 2.62 | 1.26 | 1.37 | 1.18 | |
| Inventory turnover | 4.19 | 3.52 | 3.02 | 2.84 | 2.71 | |
| ROE | 0.1 | 0.08 | 0.04 | 0.13 | 0.1 | |
| Capex per share | -11.51 | -10.57 | -8.53 | -11.02 | -17.06 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 64.2 | 65.59 | 64.65 | 66.68 | 74.6 | |
| Net income per share | 2.8 | 3.43 | 0.1 | -0.62 | 3.6 | |
| Operating cash flow per share | 7.94 | 0.01 | 8.74 | 9.13 | 9.31 | |
| Free cash flow per share | 7.94 | 0.01 | 8.74 | 9.13 | 9.31 | |
| Cash per share | 5.71 | 12.64 | 7.97 | 13.22 | 0 | |
| Book value per share | 94.25 | 89.43 | 97.72 | 87.92 | 0 | |
| Tangible book value per share | 0 | 67.01 | 0 | 65.37 | 0 | |
| Share holders equity per share | 94.25 | 89.43 | 97.72 | 87.92 | 0 | |
| Interest debt per share | 1.75 | 116.54 | 1.99 | 122.59 | 1.98 | |
| Market cap | 114.91B | 119.72B | 139.36B | 163.09B | 200.91B | |
| Enterprise value | 117.75B | 172.93B | 143.33B | 218.7B | 200.91B | |
| P/E ratio | 20.61 | 17.53 | 711.04 | -132.42 | 28.03 | |
| Price to sales ratio | 3.6 | 3.67 | 4.33 | 4.92 | 5.41 | |
| POCF ratio | 29.09 | 17.87K | 32.04 | 35.9 | 43.39 | |
| PFCF ratio | 29.09 | 17.87K | 32.04 | 35.9 | 43.39 | |
| P/B Ratio | 2.45 | 2.69 | 2.87 | 3.73 | 0 | |
| PTB ratio | 2.45 | 2.69 | 2.87 | 3.73 | 0 | |
| EV to sales | 3.69 | 5.3 | 4.46 | 6.59 | 5.41 | |
| Enterprise value over EBITDA | 25.7 | 33.23 | 36.79 | 57.77 | 35.65 | |
| EV to operating cash flow | 29.81 | 25.81K | 32.95 | 48.14 | 43.39 | |
| EV to free cash flow | 29.81 | 25.81K | 32.95 | 48.14 | 43.39 | |
| Earnings yield | 0.01 | 0.01 | 0 | 0 | 0.01 | |
| Free cash flow yield | 0.03 | 0 | 0.03 | 0.03 | 0.02 | |
| Debt to equity | 0 | 1.28 | 0 | 1.37 | 0 | |
| Debt to assets | 0 | 0.38 | 0 | 0.38 | 0 | |
| Net debt to EBITDA | 0.62 | 10.23 | 1.02 | 14.69 | 0 | |
| Current ratio | 0 | 1.06 | 0 | 0.97 | 0 | |
| Interest coverage | 2.99 | 3.14 | 1.72 | 1.49 | 3.37 | |
| Income quality | 2.83 | 0 | 88.76 | -14.76 | 2.58 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.08 | 0.09 | 0.09 | 0.09 | 0.09 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0.1 | 0 | 0.1 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 77.11 | 83.12 | 14.72 | 35 | 0 | |
| ROIC | 0.05 | 0.02 | 0.01 | 0.03 | 0 | |
| Return on tangible assets | 0 | 0.01 | 0 | 0 | 0 | |
| Graham Net | 5.71 | -140.48 | 7.97 | -155.25 | 0 | |
| Working capital | 2.84B | 2.66B | 3.96B | -1.77B | 0 | |
| Tangible asset value | 0 | 33.33B | 0 | 32.51B | 0 | |
| Net current asset value | 2.84B | -50.99B | 3.96B | -57.04B | 0 | |
| Invested capital | 0 | 1.28 | 0 | 1.37 | 0 | |
| Average receivables | 11.15B | 11.68B | 11.68B | 11.78B | 11.78B | |
| Average payables | 12.34B | 14.94B | 14.94B | 16.29B | 16.29B | |
| Average inventory | 6.03B | 6.53B | 6.53B | 7.54B | 7.54B | |
| Days sales outstanding | 0 | 64.45 | 0 | 63.91 | 0 | |
| Days payables outstanding | 0 | 290.13 | 0 | 305.68 | 0 | |
| Days of inventory on hand | 0 | 126.78 | 0 | 141.56 | 0 | |
| Receivables turnover | 0 | 1.4 | 0 | 1.41 | 0 | |
| Payables turnover | 0 | 0.31 | 0 | 0.29 | 0 | |
| Inventory turnover | 0 | 0.71 | 0 | 0.64 | 0 | |
| ROE | 0.03 | 0.04 | 0 | -0.01 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
ASTERDM.NS Frequently Asked Questions
What is Aster DM Healthcare Limited stock symbol ?
Aster DM Healthcare Limited is a AE stock and trading under the symbol ASTERDM.NS
What is Aster DM Healthcare Limited stock quote today ?
Aster DM Healthcare Limited stock price is $521.8 today.
Is Aster DM Healthcare Limited stock public?
Yes, Aster DM Healthcare Limited is a publicly traded company.
Company Profile
- Volume Average 1.06M
- Market Capitalization 243.86B
- Employee 30.33K
- CEO Dr. Nitish Shetty
- Headquarters Dubai,AE
- IPO Date 2018-02-26
-
Website
https://www.asterdmhealthcare.com 
Aster DM Healthcare Limited operates as a healthcare company in India and internationally. The company operates through Hospitals, Clinics, Retail Pharmacies, and Other segments. It provides primary, secondary, tertiary, and quaternary healthcare services through 29 hospitals, 120 clinics, 371 retail pharmacies, 114 labs, and patient experience centers under the Aster, Medcare, and Access brands. In addition, it offers healthcare retailing, diagnostic laboratories, digital health, and medical education services. The company was founded in 1987 and is headquartered in Dubai, the United Arab Emirates.
